Bavarian Nordic modtager anbefaling fra det Europæiske Lægemiddelagentur om opdatering af markedsføringstilladelse for koppe- og mpox-vaccine til at inkludere data for brugen af vaccinen mod mpox fra den virkelige verden
July 26, 2024 02:00 ET
|
Bavarian Nordic A/S
Data fra brugen af vaccinen fra den virkelige verden viser effektivitet på op mod 90% mod mpox efter vaccination med to doser MVA-BN samt at vaccinen reducerer risikoen for indlæggelse markant efter...
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
July 26, 2024 02:00 ET
|
Bavarian Nordic A/S
Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of the risk of mpox-related hospitalizations COPENHAGEN, Denmark,...
Bavarian Nordic modtager accept fra de europæiske lægemiddelmyndigheder af registreringsansøgningen for chikungunyavaccine
July 18, 2024 03:15 ET
|
Bavarian Nordic A/S
EMA påbegynder nu den fremskyndede vurdering af Bavarian Nordics chikungunyavaccine under den centraliserede procedure KØBENHAVN, Danmark, 18. juli 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i...
Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
July 18, 2024 03:15 ET
|
Bavarian Nordic A/S
EMA will now initiate its centralized review procedure under accelerated assessment for Bavarian Nordic’s chikungunya vaccine COPENHAGEN, Denmark, July 18, 2024 – Bavarian Nordic A/S (OMX: BAVA)...
Bavarian Nordic konverterer eksisterende kreditfacilitet til bæredygtighedsrelateret lån
July 01, 2024 02:30 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 1. juli 2024 – Bavarian Nordic meddelte i dag, at selskabets eksisterende uudnyttede syndikerede revolverende kreditfacilitet på DKK 1 mia. er blevet konverteret til et...
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan
July 01, 2024 02:30 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, July 1, 2024 – Bavarian Nordic today announced the conversion of its existing undrawn DKK 1 billion syndicated revolving credit facility (RCF) into a sustainability-linked loan...
Bavarian Nordic tilslutter sig globalt initiativ i kampen mod mpox i Afrika
June 28, 2024 10:27 ET
|
Bavarian Nordic A/S
Bavarian Nordic vil støtte globalt initiativ for at løse mpox-situationen i Afrika gennem tilsagn om donation af 15.000 doser mpox-vaccineDR Congo har udstedt nødbrugstilladelse for MVA-BN-vaccinen ...
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
June 28, 2024 10:27 ET
|
Bavarian Nordic A/S
Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccineEmergency Use Authorization for the MVA-BN vaccine has...
Bavarian Nordic indsender registreringsansøgning for chikungunyavaccine til de europæiske sundhedsmyndigheder
June 26, 2024 04:25 ET
|
Bavarian Nordic A/S
Myndighedsbehandling af enkelt-dose CHIKV VLP-vaccinekandidat til forebyggende immunisering mod sygdom forårsaget af chikungunyavirus for personer i alderen 12 år og opefter pågår nu både i EU og USA ...
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
June 26, 2024 04:25 ET
|
Bavarian Nordic A/S
Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older is now underway in...